Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Syringe containing liquid vaccine © Anna Shvets from Pexels

A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.

The results may lead to new approaches to protect older individuals from viruses such as the one causing the current COVID-19 pandemic and influenza.

“Older adults are at high risk of being severely affected by infectious diseases, but unfortunately most vaccines in this age group are less efficient than in younger adults,” explains lead author Ghada Alsaleh, a postdoctoral researcher at the Kennedy Institute of Rheumatology, University of Oxford, UK.

Previously, Alsaleh and colleagues showed that in older mice immune cells may become less efficient at removing cellular debris, a process called autophagy, and this leads to a poorer immune response in the animals. In the current study, they looked at samples from young and older people participating in clinical trials for vaccines against the respiratory syncytial virus and the hepatitis C virus to see if the same event happens in human immune cells called T cells. They found that autophagy increases in T cells from younger people after receiving vaccines, but this response is blunted in older people.

When they examined T cells from the older individuals in the laboratory, the team found that these cells have less of a natural compound called spermidine. Spermidine ramps up autophagy and boosts T-cell function. Supplementing these older immune cells with spermidine in the laboratory restored autophagy to the same levels seen in T cells from younger people. “Our work suggests that boosting autophagy during vaccination may help make vaccines more effective for older people,” Alsaleh says.

A small clinical trial recently tested whether giving spermidine to older adults would improve their cognitive function. As the results were positive, and spermidine did not appear to have any harmful effects, this provides some evidence that it would be safe to test whether spermidine might also be helpful for boosting the immune response of older people to vaccines.

“Our findings will inform vaccine trials in which autophagy-boosting agents, such as spermidine, are given in a controlled environment to older participants,” concludes senior author Anna Katharina Simon, Professor of Immunology at the University of Oxford. “It will be interesting to see whether these agents can enhance vaccination efficiency and help protect older people from viral infections.”

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

3D imaging reveals the role of blood vessels in hormone production

Research

New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.

Wellcome funding awarded to Oxford team to support research into heart muscle regeneration

Awards Research

An Oxford team from the Centre for Medicines Development, Department of Physiology Anatomy and Genetics and Radcliffe Department of Medicine led by Professor Jagdeep Nanchahal at the Kennedy Institute has been awarded a Wellcome Innovator Award to develop a first in class therapeutic aimed at regenerating heart muscle after heart attack.

An unexpected repair function for neutrophils

Research

In a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.